Wednesday, March 30, 2022

Arch Biopartners bags rights to bactericidal drug in wound care


Arch Biopartners has struck a deal with the University of Cincinnati to expand development of the bactericidal drug AB569 into the topical treatment of wounds. The agreement expands on an existing license covering drug-resistant respiratory infections.

AB569 is a combination of acidified nitrite and disodium ethylenediaminetetraacetic acid. Evidence the combination inhibits and kills pathogenic bacteria including the Pseudomonas aeruginosa that infects the lungs of cystic fibrosis and chronic obstructive pulmonary disease spurred interest in the respiratory applications of AB569. 

Earlier this month, researchers published data on the efficacy of AB569 against multidrug resistant Acinetobacter bacteria that the Centers for Disease Control and Prevention regard as an urgent threat. The bacteria cause acquired wound, burn, blast and ventilator-associated pneumonia infections.

Having seen the data, Arch has secured an exclusive license to patent claims covering the use of the combination in the prevention, treatment and healing of wound infections resulting from burns and blasts. The agreement supports further development of AB569 as a topical treatment for wounds. 

“With this new license, Arch now has a commercial path to develop the topical wound gel version of AB569 for clinical use. We look forward to exploring opportunities where Arch can support human trials targeting the prevention and treatment of antibiotic resistant infections in wounds,” Arch Biopartners CEO Richard Muruve said in a statement.

The market opportunity is underpinned by the morbidity and mortality associated with burn and blast injuries, notably in the military, and the limitations of existing products against the multidrug resistant Gram-negative bacteria that can infect such wounds. Such bacteria can mutate to nullify the effects of multiple antibiotic regimens.

There are reasons to think AB569 may fare better. An earlier study found AB569 compromised more than 30 vital pathways in a pathogen that infects wounds. By acting on the biosynthesis of DNA, RNA, protein and ATP, the combination could quickly kill wound pathogens without giving rise to bacteria that are resistant to all of its bactericidal properties. 



Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...